Withdrawal Mgmt denied due to quantity / dose limits by Humana?

Humana's specific coverage criteria for withdrawal mgmt are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Applies Quantity Limits to Withdrawal Management — and How to Appeal

Humana's quantity-limit policies for withdrawal management most commonly appear as limits on the number of covered detoxification episodes per benefit period, limits on covered days per episode, or both. A denial on quantity-limit grounds means either that the patient has already used the plan's covered allotment for the benefit year, or that the requested duration of a single episode exceeds the plan's per-episode day limit. Both types of quantity limits are subject to appeal — especially when the treating clinician can document that the patient's clinical condition requires additional episodes or a longer duration than the plan's standard limit.

## Why This Denial Is Appealable

Quantity-limit denials are clinical coverage decisions subject to full appeal rights. Under ACA Section 2719, non-grandfathered plan members may request independent external review after exhausting internal appeals. Under ERISA Section 503, employer-plan members are entitled to a full-and-fair internal review. The external-review window is generally 180 days from denial; expedited 72-hour review is available when delay would jeopardize life or health. The Mental Health Parity and Addiction Equity Act (MHPAEA) is a powerful tool here: if Humana limits withdrawal management episodes or days but imposes no equivalent per-year limit on medically supervised management of comparable physiologic conditions (such as other medical conditions requiring repeated inpatient management), that is a parity violation. Request the non-quantitative treatment limitation analysis if needed.

## Concrete Appeal Steps

1. Request the denial letter with the specific quantity limit invoked and the benefit-period dates. 2. Obtain Humana's behavioral health coverage policy and the quantity-limit provisions — note whether limits apply per episode, per year, or over the lifetime of the benefit. 3. File the internal appeal with documentation showing clinical necessity for additional days or episodes. 4. Request MHPAEA parity information — Humana must disclose the criteria used to set quantity limits for mental health and substance use disorder benefits versus medical/surgical benefits. 5. Escalate to external review if the internal appeal is denied.

## Documentation to Gather

• Diagnosis confirmation: Current substance use disorder diagnosis with documented acute withdrawal severity requiring managed care.
• Prior-episode history: Dates and outcomes of any prior withdrawal episodes in the benefit period — not to justify repetition, but to show the chronic, relapsing nature of the condition and the clinical necessity of each episode.
• Clinical severity: Treating clinician's notes documenting that the patient's current presentation requires the duration or number of episodes being requested, including evidence that a shorter episode or fewer episodes would be clinically unsafe or ineffective.
• Prescriber medical-necessity letter: A signed letter from the treating addiction medicine specialist or physician explaining why the quantity limit is clinically inappropriate for this patient and why additional covered days or episodes are medically necessary.
• MHPAEA parity argument: If applicable, identify the comparable medical/surgical benefit and ask Humana to demonstrate that the same quantity limits apply.

## Criteria-Mapping Structure

List each quantity-limit provision cited in the denial. For each, provide the treating clinician's documented clinical rationale for exceeding the limit. Pair this with a MHPAEA parity argument if the limit appears to be applied more restrictively to substance use disorder care than to comparable medical benefits.